Mapracorat (
INN
Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...
, code names BOL-303242-X, ZK-245186
) is an
anti-inflammatory drug
Anti-inflammatory is the property of a substance or treatment that reduces inflammation or swelling. Anti-inflammatory drugs, also called anti-inflammatories, make up about half of analgesics. These drugs remedy pain by reducing inflammation as ...
belonging to the experimental class of
selective glucocorticoid receptor agonists (SEGRAs). It is in
clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...
s for the topical treatment of
atopic dermatitis
Atopic dermatitis (AD), also known as atopic eczema, is a long-term type of inflammation of the skin ( dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over tim ...
,
inflammation following
cataract surgery
Cataract surgery, also called lens replacement surgery, is the removal of the natural lens of the eye (also called "crystalline lens") that has developed an opacification, which is referred to as a cataract, and its replacement with an intraocul ...
,
and
allergic conjunctivitis.
Preliminary investigation for the treatment of
keratoconjunctivitis sicca
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. Symptoms range ...
has been conducted in cellular models.
Clinical trials
Phase II clinical trials with mapracorat started in summer 2009. One trial was a
double blind dose finding study for an
ointment against atopic dermatitis. It tested concentrations of 0.01%, 0.03% and 0.1% versus
placebo
A placebo ( ) is a substance or treatment which is designed to have no therapeutic value. Common placebos include inert tablets (like sugar pills), inert injections (like Saline (medicine), saline), sham surgery, and other procedures.
In general ...
over four weeks in around 64 patients. This trial was conducted by Intendis, a part of
Bayer HealthCare Pharmaceuticals specialized on
dermatology
Dermatology is the branch of medicine dealing with the skin.''Random House Webster's Unabridged Dictionary.'' Random House, Inc. 2001. Page 537. . It is a speciality with both medical and surgical aspects. A List of dermatologists, dermatologist ...
, and completed in September or October 2010.
The other trial, also with a double blind design, evaluated an
ophthalmic suspension for the treatment of inflammation following cataract surgery. Various concentrations and dosing schemes were tested versus placebo in about 550 patients. The study was conducted by
Bausch & Lomb
Bausch + Lomb is an eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The compan ...
and completed in September 2010.
Its successor study, a phase III trial, started in November 2010 and completed in August 2011.
no study results are available.
See also
*
AZD-5423
AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obs ...
*
Dagrocorat
Dagrocorat (developmental code names PF-00251802, PF-251802) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed.https: ...
*
Fosdagrocorat
Fosdagrocorat (developmental code names PF-04171327 and PF-4171327; also known as dagrocorat 2-(dihydrogen phosphate)) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treat ...
References
Anti-inflammatory agents
Benzofurans
Fluoroarenes
Immunosuppressants
Quinolines
Selective glucocorticoid receptor modulators
Trifluoromethyl compounds
{{dermatologic-drug-stub